BioRestorative Therapies ... (BRTX)
| Bid | 1.67 |
| Market Cap | 13.13M |
| Revenue (ttm) | 401K |
| Net Income (ttm) | -8.98M |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -1.51 |
| Forward PE | -2.11 |
| Analyst | Strong Buy |
| Ask | 2.07 |
| Volume | 25,105 |
| Avg. Volume (20D) | 381,398 |
| Open | 1.70 |
| Previous Close | 1.73 |
| Day's Range | 1.70 - 1.77 |
| 52-Week Range | 1.03 - 2.55 |
| Beta | 0.36 |
About BRTX
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous ...
Analyst Forecast
According to 1 analyst ratings, the average rating for BRTX stock is "Strong Buy." The 12-month stock price forecast is $18, which is an increase of 928.57% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · seekingalpha.com
BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call TranscriptBioRestorative Therapies, Inc. (NASDAQ:BRTX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Lance Alstodt – Chairman and Chief Exe...